

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
570 daily bars · split adjusted
Current price $12.27
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 18, 26 |
Daily · Wilder smoothing
| Leerink Partners |
| maintain |
| Outperform |
| Outperform |
| Aug 10, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 6, 26 | Guggenheim | maintain | Buy | Buy |
| Aug 6, 26 | Truist Securities | maintain | Buy | Buy |
| Jul 14, 26 | Truist Securities | maintain | Buy | Buy |
| Jul 9, 26 | RBC Capital | maintain | Outperform | Outperform |
| May 7, 26 | UBS | maintain | Buy | Buy |
| Mar 10, 26 | RBC Capital | maintain | Outperform | Outperform |
| Mar 6, 26 | Leerink Partners | maintain | Outperform | Outperform |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 66.75 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 88.73 | Oscillator | Sell |
| Williams %R (14) | -10.10 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.40 (Hist 0.11) | Oscillator | Strong Buy |
| Average Directional Index (14) | 29.17 (+DI 28.6 / -DI 9.7) | Trend | Strong Buy |
| EMA 20 | 11.56 | MA | Strong Buy |
| SMA 20 | 11.31 | MA | Strong Buy |
| EMA 50 | 11.11 | MA | Strong Buy |
| SMA 50 | 11.04 | MA | Strong Buy |
| SMA 200 | 9.90 | MA | Strong Buy |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 23, 2026 | 2026-10-23 16:42:52 | View |
| 4 | Sep 29, 2026 | 2026-09-29 12:54:27 | View |
| 4 | Sep 29, 2026 | 2026-09-29 12:54:00 | View |
| 4 | Sep 29, 2026 | 2026-09-29 12:52:02 | View |
| 8-K | Sep 4, 2026 | 2026-09-04 16:16:17 | View |
| 10-Q | Aug 10, 2026 | 2026-08-10 16:07:49 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 16:16:33 | View |
| 4 | Jul 2, 2026 | 2026-07-02 13:16:51 | View |
| 8-K | Jun 30, 2026 | 2026-06-30 16:33:53 | View |
| 4 | Jun 8, 2026 | 2026-06-08 12:50:38 | View |
Proxy statement (DEF 14A) disclosures
FY2025 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | ARDT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 22.3x | 18.6x · sector 20.7x | In line |
| Forward P/E (FY26E) | 12.8x | EPS est. 0.95 | Discount |
| Price / Book | 1.3x | 2.0x | Discount |
| Price / Sales | 0.3x | 0.4x | Discount |
| EV / EBITDA | 8.1x | 6.5x | Elevated |
| Return on equity | 5.2% | — | Weak |
| Gross margin | 30.0% | 88.0% | Below hist. |
| Debt / Equity | 1.68 | 2.13 | Levered |
| Piotroski / Altman Z | 5/9 | Z 2.05 | Grey zone |
Discounted cash flow model
Stock news · updated daily
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Gaurav Khanna as chief digital & information officer. In this role, Khanna will lead Ardent's technology, data, AI and digital strategy to support patient care, operational excellence and long-term growth. “We're committed to building the capabilities that will help Ardent continue to deliver exceptional ca.
Shares of Ardent Health, Inc. (NYSE: ARDT - Get Free Report) have earned an average rating of "Hold" from the fifteen ratings firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its third quarter 2026 results after the market closes on Wednesday, Nov. 4, 2026. A conference call will be held the following day, Thursday, Nov. 5, 2026, at 10 a.m. ET to review the Company's financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying presen.
Ardent Health (NYSE: ARDT - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends. Profitability This table compares Ardent Health and
Ardent Health remains a 'buy' as shares are deeply undervalued despite recent profitability declines. ARDT revenue continues to grow, with management projecting $6.4–$6.7 billion for the year, but EBITDA and cash flow are expected to fall short of prior results. Professional fees pressured margins, but management anticipates this cost trend will moderate in the second half, signaling potential stabilization.
Shares of Ardent Health, Inc. (NYSE: ARDT - Get Free Report) have received an average recommendation of "Hold" from the fifteen brokerages that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and seven have assigned a buy recommendation to the company.
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
BRENTWOOD, Tenn.--(BUSINESS WIRE)--Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that 13 hospitals across its network earned recognition in U.S. News & World Report's 2026-2027 Best Hospitals rankings, the publication's 37th annual assessment of hospital quality. The honors include a Best Regional Hospital designation, regional specialty rankings and 34 High Performing ratings across procedures and conditi.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 0.18 | 0.12 | Miss -34.0% | $1.62B |
| May 5, 2026 | 0.18 | 0.28 | Beat 55.6% | $1.60B |
| Mar 4, 2026 | 0.35 | 0.32 | Miss -8.0% | $1.61B |
| Nov 12, 2025 | 0.42 | 0.52 | Beat 22.6% | $1.58B |
| Aug 5, 2025 | 0.30 | 0.52 | Beat 73.3% | $1.65B |
| May 6, 2025 | 0.21 | 0.29 | Beat 38.1% | $1.50B |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 25, 26 | Lumsdaine Alfred | officer: Chief Financial Officer | F-InKind | 3,389 @ $10.54 | $35.72K |
| Sep 25, 26 | Petrovich Stephen C. | officer: EVP, GC and Secretary | F-InKind | 788 @ $10.54 | $8.31K |
| Sep 25, 26 | Byers David Raynor | officer: SVP & Chief Accounting Officer | F-InKind | 524 @ $10.54 | $5.52K |
| Jul 1, 26 | Caspers Dave | director, officer: CEO and President | A-Award | 103,653 | — |
| Jun 5, 26 | Demichiei Robert | director | P-Purchase | 11,260 @ $8.73 | $98.30K |
| Jun 5, 26 | Lumsdaine Alfred | officer: Chief Financial Officer | P-Purchase | 10,000 @ $8.81 | $88.10K |
| Apr 1, 26 | Bulgarelli Peter J. | director | A-Award | 14,231 | — |
| Apr 1, 26 | Havdala Ellen | director | A-Award | 14,231 | — |